CME Activities
FDA Approves Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma: A Review of Its Benefits and Risks - Targeted Therapy for the Treatment of Basal Cell Carcinoma and Melanoma: Implications for Patients and Healthcare Practitioners
- Metastatic Melanoma: Which Treatment, When?
- Unanswered Questions About Margin Recommendations for Primary Cutaneous Melanoma
- Smaller Excision Margin Safe in Removal of Thick Melanomas
- Cell Transfer Immunotherapy for Metastatic Solid Cancer -- What Clinicians Need to Know
Latest Clinical Briefs in Melanoma
About Melanoma
-
Melanoma accounts for the majority of skin cancer-related deaths while remaining one of the rarer forms of skin cancer. Historically, advanced metastatic melanoma has been difficult to treat, but newer targeted and immune-based therapies have recently shown promise in clinical trials. Practitioners are challenged to keep up to date on the latest data regarding the efficacy of these agents, both alone and in combination with the current standard of care, in anticipation of an expanding armamentarium of effective therapies for melanoma.